Independent multi-center trial shows that Getinge's NAVA ventilation mode shortens time of mechanical ventilation by almost 35% for adult ICU patients
Getinge's Neurally Adjusted Ventilatory Assist (NAVA) technology demonstrated significant clinical effectiveness in the NAVIATOR trial, reducing mechanical ventilation time for adult patients with acute respiratory failure by nearly 35%. Conducted across 14 centers, the trial involved 306 patients and highlighted improvements in health economics by potentially freeing up ICU resources. The study supports NAVA's routine use in intensive care settings. This advancement indicates continued growth potential for Getinge's innovative ventilation solutions in the market.
- NAVA technology reduced mechanical ventilation time from 12 to 8 days, a 35% decrease.
- Positive effects observed in patient recovery and health economics by freeing ICU resources.
- NAVIATOR trial involved 306 patients, emphasizing the credibility of the findings.
- None.
GOTHENBURG, Sweden, Sept. 30, 2020 /PRNewswire/ -- The clinical effectiveness of Getinge's patented Neurally Adjusted Ventilatory Assist (NAVA), which uses the patient's own respiratory drive to control ventilator assistance, is supported in the NAVIATOR trial. According to the NAVIATOR trial, NAVA significantly increased the number of ventilator-free days and shortened the time of mechanical ventilation (MV) for adult patients with acute respiratory failure (ARF)1.
"This large multi-center independent trial supports that NAVA has significant positive clinical effects for adult patients in intensive care units (ICU). The study showed that through the use of NAVA, the days on mechanical ventilation could be reduced from 12 to 8 days, a four-day reduction or close to
The NAVIATOR randomized, controlled trial (RCT), which was conducted in 14 centers located in Spain and one in China, included 306 patients with acute respiratory failure (ARF) from several etiologies, such as pneumonia, sepsis, COPD and post-surgical patients. Earlier this year, an increase in ventilator free-days was also reported in two single center randomized, controlled trials completed in China and UK.
One of the principal investigators Dr. Jesus Villar, at the Research Unit, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Spain, concludes: "This is the first RCT that on a multicenter scale examined the effectiveness of NAVA in reducing the dependency on mechanical ventilation of patients with ARF with an expected duration of mechanical ventilation more than 72 hours. The results confirmed that NAVA is a ventilation mode for routine used in a heterogeneous population of patients with ARF, and can make the transition to spontaneous breathing in conjunction with gradual removal of sedative agents much quicker and easier."
Getinge is highlighting the groundbreaking technology of NAVA in a new video, which showcases Sabina Checketts, who was born 12 weeks too early with 50/50 chance at survival. Checketts is now a neonatal doctor, using new therapies and sophisticated technology to improve outcomes for premature babies.
Watch the mini-documentary about the NAVA technology, featuring Sabina Checketts.
This is NAVA
The NAVA and NIV NAVA ventilation modes are available i Getinge's Servo-u, Servo-n and Servo-i ventilator systems, and were designed to provide optimal patient-ventilator interaction for adult, pediatric and neonatal patients, invasively or non-invasively ventilated.
NAVA has been commercialized exclusively by Getinge since it was invented by Dr. Christer Sinderby in the mid-1990s and commercially released in 2007. Since then the technology has been further developed by Getinge, for example in terms of usability, performance and automation.
"This is one of the reasons why we have been outgrowing the market in this space for a while now. But we believe it has only started. We are far from fully penetrated when it comes to the potential end-users, so we will do all we can to ensure that NAVA is available to even more patients in the future", says Jens Viebke.
The ventilation mode is based on monitoring of the neural output generated by the respiratory centers in the brain. By using the same electrical signal that activates the human diaphragm, the ventilator is continuously fully synchronized and proportional with the patient's own respiratory efforts...
"NAVA is designed to deliver what the patient wants," Jens Viebke explains. "Since it is the patient's own physiological respiratory drive that controls the tidal volume and respiratory pattern, it promotes both lung- and diaphragm spontaneous breathing and improves the patient's overall ICU experience"
Read the research article "Neurally adjusted ventilatory assist in acute respiratory failure: a randomized controlled trial" here.
Read more about the NAVA technology on: www.getinge.com/int/product-catalog/nava/ and www.getinge.com/int/life-defining-moments/
1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474954/pdf/134_2020_Article_6181.pdf
Media contact:
Anna Appelqvist
Vice President Corporate Communications
Phone: +46 (0)10 335 5906
E-mail: anna.appelqvist@getinge.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Independent multi-center trial shows that Getinge’s NAVA ventilation mode shortens time of mechanical ventilation | |
https://news.cision.com/getinge/i/getinge---jens-viebke,c2832452 | Getinge - Jens Viebke |
Sabina Checketts |
View original content:SOURCE Getinge
FAQ
What are the results of the NAVIATOR trial for Getinge's NAVA technology?
When was the NAVIATOR trial conducted for Getinge's NAVA ventilation mode?
What impact does NAVA technology have on ICU resources according to the NAVIATOR trial?
Where was the NAVIATOR trial conducted?
What is the stock impact of the NAVIATOR trial results for Getinge?
